Since more than two decades, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is considered the gold standard for patients with acute coronary syndrome (ACS) as well as for those with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI) [1]. The more potent P2Y12 inhibitors prasugrel and ticagrelor have shown to reduce ischemic events at the cost of increased bleeding compared with clopidogrel [2,3]. Therefore, a 12-month DAPT with potent P2Y12 inhibitors represents the standard-of-care after ACS and may be considered after PCI in CCS patients in specific high ischemic risk situations [4–6].
